Australian Study Reveals Significant Cost Savings and Market Impact From Biosimilars

September 10, 2025

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market.

Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD

September 09, 2025

SYSA1902 Biosimilar Proves Equivalent to Reference Ustekinumab in Plaque Psoriasis

September 08, 2025

The Top 5 Biosimilar Articles for the Week of September 1

September 05, 2025

Japanese Trial Supports Widespread Use, Safety of Infliximab Biosimilar Use

September 04, 2025

FDA Approves Imuldosa, a Biosimilar to Stelara

October 11th 2024

By Skylar Jeremias

Article

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share

October 11th 2024

By Skylar Jeremias

Article

Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.

The Top 5 Biosimilar Articles for the Week of October 7

October 11th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of October 7, 2024.

Sandoz Report: A Unified Approach to Overcoming Drug Shortages

October 10th 2024

By Skylar Jeremias

Article

A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.

Duke Publishes Recommendations for Developing CGT Biosimilars

October 9th 2024

By Skylar Jeremias

Article

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex biologics limit competition, requiring policies that support the development of biosimilars to enhance affordability and patient access.

Biosimilar Rituximab Safe, Effective for SLE After Switching

October 8th 2024

By Cameron Santoro

Article

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus erythematosus (SLE).

BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US

October 7th 2024

By Sarfaraz K. Niazi, PhD

Article

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.

Biosimilars Policy Roundup for September 2024—Podcast Edition

October 6th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.

Treatment Persistence, Safety After Switching to Infliximab Biosimilars in Canadians With IBD

October 5th 2024

By Deana Ferreri, PhD

Article

A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory bowel disease (IBD) on maintenance therapy 1 year post-switch.

The Top 5 Biosimilar Articles for the Week of September 30

October 4th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of September 30, 2024.